comprehensive -WSS

comprehensive

author：entertainment 2025-09-06 02:03:52 - browse：3984

Brain cancer — Michelle Monje/Stanford University/NIH

Tocagen (TOCA) said Tuesday that a Phase 3 clinical trial involving a novel gene therapy for aggressive brain tumors will continue to a final analysis later this year, following an interim look at patient survival data conducted by independent monitors. Tocagen’s stock price dropped sharply.

The San Diego-based biotech pitched the study’s continuation as an encouraging sign for its gene therapy called Toca 511/Toca FC, which is designed to deliver a localized chemotherapy directly to the site of brain tumors.

“We believe the longer-term follow-up of patients in the final analysis, particularly for those randomized in the second enrollment period, will be important in assessing both primary and secondary endpoints,” said Tocagen CEO Marty Duvall, in a statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Paxlovid should be available without a positive Covid test

leisure time

hotspot

WSS

FDA seeks to regulate lab

UnitedHealth’s board chair also owns a personal investment firm

STAT Readout Newsletter: Today's biggest biotech updates

Data show record exodus of life scientists from academia

Why do women spend more than men on medical expenses?

Researchers use wearables data and AI to predict preterm birth risk

hotspot

comprehensive

explore

Sports medicine is finally prioritizing gender equality

UnitedHealth’s board chair also owns a personal investment firm

In age of alternative facts, a scholarly course on calling out crap

Ionis has late

Medical leaders decry Supreme Court decision on affirmative action

Senate committee scrutinizes Medicare Advantage brokers

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Shingles, which affected Dianne Feinstein, is on the rise

Virginia high school admissions case could be legal follow

Kaiser Permanente unions announce official strike date

focus

Shingles, which affected Dianne Feinstein, is on the rise

Impact of Dobbs ruling felt at reproductive medicine meeting

Data show record exodus of life scientists from academia

STAT Readout Newsletter: Today's biggest biotech updates

Hospital price transparency does save money, advocate argues

Hospital price transparency does save money, advocate argues

entertainment

leisure time

hotspot

focus